AMCP's Q3 2026 Precision Medicine Bulletin is now available.
Stay informed on the latest developments shaping precision medicine access, coverage, and implementation across managed care. AMCP's quarterly Precision Medicine Bulletin delivers updates on ongoing research, policy engagement, educational resources, clinical guidelines, and emerging evidence relevant to payers, manufacturers, providers, and other healthcare stakeholders. Launched as part of the AMCP Precision Medicine Initiative, the bulletin serves as a central source for insights, publications, and activities advancing the appropriate use of biomarker testing and precision medicine.
In the Q3 2026 issue, readers will find updates on AMCP's recommendations to the National Comprehensive Cancer Network (NCCN), newly accepted precision medicine publications, current research initiatives, educational resources, and a review of recent NCCN biomarker testing guideline updates for non-small cell lung cancer.
Whether you're evaluating coverage policies, generating evidence, supporting clinical decision-making, or tracking developments in personalized care, the Precision Medicine Bulletin provides practical insights and resources to help you stay current on one of healthcare's fastest-evolving fields.
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
